P-Selectin antagonism causes dose-dependent venous thrombosis inhibition

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 423-429

  Myers D D , Jr ^a   Schaub, R ^a   Wrobleski, S K ^a   Londy III, F J ^a   Fex, B A ^a   Chapman, A M ^a   Greenfield, L J ^a   Wakefield, T W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antagonism; Inflammation; Selectin; Thrombosis; Venous

Indexed keywords

DALTEPARIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; INFERIOR CAVA VEIN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; THROMBOCYTE AGGREGATION INHIBITION; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 0035081022     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615622     Document Type: Article

References (26)

1. Socioeconomic impact of chronic venous insufficiency and leg ulcers
2. Neutrophils and deep venous thrombosis
3. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules
4. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis
5. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis
6. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy
7. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats
8. Pharmacokinetics, pharmacodynamics, allometry, and dose selection for rPSGL-Ig for phase I trial
9. "Bulls-Eye" sign on gadolinium-enhanced magnetic resonance venography determines thrombus presence and age: A preliminary study
10. Role of PSGL-1 binding to selectins in leukocyte recruitment
11. Mechanisms of platelet binding to neutrophils in contact with damaged arterial surfaces under flow conditions
12. Effect of recombinant soluble P-selectin glycoprotein ligand-1 on leukocyte-endothelium interaction in vivo. Role in rat traumatic shock
13. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1
14. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand
15. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: Role of selectins
16. Anti-thrombotic effect of a recombinant soluble P-selectin glycoprotein ligand-1 chimera in a rat model of thrombosis
17. Effect of recombinant PSGL-I (rPSGL-Ig) on vascular injury and thrombosis following venous stasis
18. A recombinant soluble P-selectin glycoprotein ligand-1 chimera has a thrombolytic effect in a rat model of thrombosis
19. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor
20. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo
21. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
22. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis
23. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
24. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis
25. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model